BIOXCEL THERAPEUTICS INC

BioXcel files for Chapter 11 and sells its BXCL501 drug to Teva for $57.5 million, a key move to liquidate assets and provide liquidity to creditors.

Bioxcel Therapeutics has announced key research publications and market insights, highlighting its progress in neuroscience and immuno-oncology, and positioning it as a promising investment opportunity.

BioXcel Therapeutics Inc. continues to make waves in the biotechnology sector with its innovative approach to drug development, recent research publications, and expert endorsements signaling a promising trajectory.

Bioxcel Therapeutics Inc’s stock has experienced a rollercoaster ride, plummeting from a high of $16.64 to a 52-week low of $1.17, raising concerns about the company’s financial sustainability and ability to deliver on its innovative AI-driven drug …